Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Nociceptin orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice
Autore:
Hiramatsu, M; Inoue, K;
Indirizzi:
Meijo Univ, Fac Pharmaceut Sci, Dept Chem Pharmacol, Nagoya, Aichi 4688503, Meijo Univ Nagoya Aichi Japan 4688503 m Pharmacol, Nagoya, Aichi 4688503,
Titolo Testata:
BRITISH JOURNAL OF PHARMACOLOGY
fascicolo: 3, volume: 127, anno: 1999,
pagine: 655 - 660
SICI:
0007-1188(199906)127:3<655:NOFANO>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
INDUCED DELAYED AMNESIA; LONG-TERM POTENTIATION; OPIOID RECEPTOR AGONIST; DYNORPHIN A-(1-13); RAT HIPPOCAMPUS; BINDING; BRAIN; IDENTIFICATION; TRANSMISSION; BEHAVIOR;
Keywords:
nocistatin; nociceptin; orphanin FQ; kappa-opioid receptor; dynorphin A; spontaneous alternation; passive avoidance; learning and memory; cholinergic neuronal system;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Hiramatsu, M Meijo Univ, Fac Pharmaceut Sci, Dept Chem Pharmacol, Nagoya, Aichi 4688503, Meijo Univ Nagoya Aichi Japan 4688503 Nagoya, Aichi 4688503,
Citazione:
M. Hiramatsu e K. Inoue, "Nociceptin orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice", BR J PHARM, 127(3), 1999, pp. 655-660

Abstract

1 Nociceptin, also known as orphanin FQ, is an endogenous ligand for the orphan opioid receptor-like receptor 1 (ORL1) and involves in various functions in the central nervous system (CNS). On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced allodynia and hyperalgesia.2 Although ORL1 receptors which display a high degree of sequence homologywith classical opioid receptors are abundant in the hippocampus, little isknown regarding their role in learning and memory.3 The present study was designed to investigate whether nociceptin/orphanin FQ and nocistatin could modulate impairment of learning and memory induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice.4 While nocistatin (0.5-5.0 nmol mouse(-1), i.c.v.) administered 30 min before spontaneous alternation performance or the training session of the passive avoidance task, had no effect on spontaneous alternation or passive avoidance behaviours, a lower per cent alternation and shorter median step-down latency in the retention test were obtained in nociceptin (1.5 and/or 5.0 nmol mouse(-1), i.c.v.)-treated normal mice.5 Administration of nocistatin (1.5 and/or 5.0 nmol mouse(-1), i.c.v.) 30 min before spontaneous alternation performance or the training session of the passive avoidance task, attenuated the scopolamine-induced impairment ofspontaneous alternation and passive avoidance behaviours.6 These results indicated that nocistatin, a new biologically active peptide, ameliorates impairments of spontaneous alternation and passive avoidance induced by scopolamine, and suggested that these peptides play opposite roles in learning and memory.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 10:47:04